

FIGURES

Figure 1





Figure 2



SUBSTITUTE SHEET (RULE 26)

Figure 3

NAFLD Activity Score




Figure 3 (continued)






Figure 3 (continued)

Ballooning Score




Compound 1

Fibrosis Area



Compound 1



Dose [mg/kg]	Cmax* [ng/mL]	AUC [ng/mL*h]
100	56.4	299
300	84.1	453
1000	162.1	651

* Cmax after first administration (tmax: 0.5h)

Figure 5




Figure 5 (continued)




Figure 5 (continued)




Figure 6





Figure 7



Clinical PK data (CEC-2/BIO)		$C_{\max} / IC_{(10-90)}$		
Drug level	$C_{\max}$ ($\equiv$ drug conc. at target site)	IC_{10} (18 ng/mL)	IC_{50} (101 ng/mL)	IC_{90} (346.2 ng/mL)
10 mg	59.8 ng/mL	3,3	0,6	0,2
20 mg	127.0 ng/mL	7,1	1,3	0,4
50 mg	375.0 ng/mL	20,9	3,7	1,1
100 mg	840.0 ng/mL	46,7	8,3	2,4

Figure 8




Figure 9

Reduction of fibrotic area vs. Cmax




Figure 10





Figure 11



SUBSTITUTE SHEET (RULE 26)

Figure 12

Trial design schematic of Example 14

